Evidence for NADPH oxidase activation by GPR40 in pancreatic β-cells

Gabriela Nunes Marsiglio-Librais *, Eloisa Aparecida Vilas-Boas a,b, Christopher Carlein b, Markus Daniel Alexander Hoffmann b, Leticia Prates Roma a,* and Angelo Rafael Carpinelli *

a Department of Physiology and Biophysics, Institute of Biomedical Sciences, University of São Paulo (USP), São Paulo, Brazil; b Department of Biophysics, Center for Human and Molecular Biology, CIPMM, Saarland University, Homburg/Saar, Germany

ABSTRACT

Objective: Investigate the involvement of the fatty acids receptor GPR40 in the assembly and activation of NADPH oxidase and the implications on pancreatic β-cell function.

Methods: BRIN-BD11 β-cells were exposed to GPR40 agonist (GW9508) or linoleic acid in different glucose concentrations. Superoxide and H2O2 were analyzed, respectively, by DHE fluorescence and by fluorescence of the H2O2 sensor, roGFp2-Orp1. Protein contents of p47phox in plasma membrane and cytosol were analyzed by western blot. NADPH oxidase role was evaluated by p22phox siRNA or by pharmacological inhibition with VAS2870. NOX2 KO islets were used to measure total cytosolic calcium and insulin secretion.

Results: GW9508 and linoleic acid increased superoxide and H2O2 contents at 5.6 and 8.3 mM of glucose. In addition, in 5.6 mM, but not at 16.7 mM of glucose, activation of GPR40 led to the translocation of p47phox to the plasma membrane. Knockdown of p22phox abolished the increase in superoxide after GW9508 and linoleic acid. No differences in insulin secretion were found between wild type and NOX2 KO islets treated with GW9508 or linoleic acid.

Discussion: We report for the first time that acute activation of GPR40 leads to NADPH oxidase activation in pancreatic β-cells, without impact on insulin secretion.

Introduction

Although glucose is the main secretagogue of insulin, other molecules including hormones, amino acids and free fatty acids (FFAs) also modulate insulin secretion [1–4]. G protein-coupled receptors activated by FFAs, namely GPRs, were identified in different cell types [5]. Among them, GPR40 is highly expressed in pancreatic β-cells and has a great affinity for saturated and unsaturated long-chain FFAs. The activation of GPR40 triggers signaling cascades involved in the process of insulin secretion [6–8]. The complete picture following GPR40 activation is still unknown, but it involves activation of phospholipase C (PLC), via Gαq protein, leading to the hydrolysis of phosphatidylinositol 4,5-biphosphate (PIP2) in diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3), which respectively activates protein kinase C (PKC) and activation of phospholipase C (PLC), via Gαq protein, leading to the hydrolysis of phosphatidylinositol 4,5-biphosphate (PIP2) in diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3), which respectively activates protein kinase C (PKC) and p22phox, forming the cytosolic subunits p67phox, p47phox and p22phox, mobilizes calcium from endoplasmic reticulum [7,9,10].

Importantly, it was shown that GPR40 inhibition impairs FFA-stimulated insulin secretion in vitro [1]. In addition, pancreatic islets of human donors with type 2 diabetes mellitus have diminished expression of GPR40 [11] and obese individuals have a higher frequency of GPR40 mutations, leading to impairment of insulin secretion [12].

Due to these findings, GPR40 was proposed as a valuable target for the development of new drugs for the treatment of type 2 diabetes. Thus, in the past years, several agonist molecules have been developed and used in in vitro, mouse models [13–18] and clinical trials [18–22] aiming to understand the impact of activating GPR40 for whole-body glycemic control.

Reactive oxygen species (ROS) have been suggested as signaling molecules important for insulin secretion, reviewed in [23]. Two important sources of ROS in pancreatic β-cells are the electron transport chain and the NADPH oxidases. NADPH oxidase produces superoxide and was originally described in phagocytic cells in which it is of great importance to eliminate bacteria and other pathogens [24,25]. The complex is composed by two membrane subunits, gp91phox and p22phox, forming the flavocytochrome b558, catalytic core of the enzyme, the cytosolic subunits p67phox, p47phox and p40phox, and the small GTPase Rac [24,26].

For activation of the complex, the organizer subunit p47phox is phosphorylated by PKC, promoting the translocation of all cytosolic subunits to the membrane and their association with the membrane subunits. The assembled complex produces superoxide anions through the reduction of oxygen molecule, utilizing NADPH as an electron donor [24,26].

Despite its importance in phagocytes, NADPH oxidase is ubiquitously expressed [25]. Our group has previously demonstrated the expression of NADPH oxidase subunits in human and rodent pancreatic islets and insulin-secreting β-cell lines [27,28]. The superoxide produced may be involved in the process of insulin secretion, since the acute inhibition of NADPH oxidase by DPI or p47phox oligonucleotide antisense promote the reduction of glucose-stimulated insulin secretion (GSIS) [29]. NADPH oxidase also participates in the palmitate-induced superoxide production and insulin secretion [30]. The mechanism, however, is still unclear.

KEYWORDS
GPR40; NADPH oxidase; ROS; p47phox translocation; BRIN-BD11; GW9508; Linoleic acid; NOX2 KO islets; roGFp2-Orp1; insulin secretion

CONTACT Gabriela Nunes Marsiglio-Librais gabinunes21@yahoo.com.br Department of Physiology and Biophysics, Institute of Biomedical Sciences, University of São Paulo (USP), Av. Prof. Lineu Prestes 1524, São Paulo, SP, Brazil
*Equal contribution.
© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
On the other hand, NOX2 KO islets were shown to secrete more insulin upon glucose stimulation, and NOX2, therefore, would act as a negative modulator of insulin secretion, an effect attributed to modulation of cAMP [31,32]. In addition, inhibition of NADPH oxidase rescued the decreased glucose oxidation, elicited by oleate treatment. Thus, it is clear that much controversy exists regarding the role of NADPH oxidase in the regulation of insulin secretion and that stimulation of GPR40 activators of GPR40 [13,33,34].

Considering the possible role of NADPH oxidase in the regulation of insulin secretion and that stimulation of GPR40 by FFAs leads to an increase in GSIS through PKC, which is a common pathway on the activation of NADPH oxidase; the aim of this work was to evaluate the involvement of GPR40 in the activation of NADPH oxidase and consequently the production of reactive oxygen species (ROS) production by pancreatic β-cells. Finally, we also evaluated insulin secretion and calcium homeostasis in NOX2 KO islets upon GPR40 activation. In this study, we used the agonist GW9508 and the unsaturated long-chain FFA linoleic acid, which are potent activators of GPR40 [13,33,34].

MATERIALS and methods

Reagents

Reagents for SDS-PAGE were obtained from Bio-Rad (Richmond, CA, USA); dihydroethidium (DHE), RPMI 1640 culture medium, heat-inactivated fetal bovine serum, Opti-MEM medium, Lipofectamine 2000, RIPA lysis buffer and Fura-2 AM were obtained from Thermo Fischer Scientific (Waltham, MA, USA); Bradford Reagent and linoleic acid were obtained from Sigma-Aldrich (St. Louis, MO, USA); Insulin Ultra-Sensitive Assay kit was obtained from Cisbio (Codolet, France); GW9508 was obtained from Tocris Bioscience (Bristol, England, UK); VAS2870 was obtained from Enzo Life Sciences (Farmingdale, NY, USA); p22phox siRNA (#sc-61892), control siRNA (#sc-37007), anti-p47phox (#sc-14015; dilution 1:1000 in 5% BSA in 3% skimmed milk in TBST), anti-p22phox (#sc-271968; dilution 1:500 in 5% BSA in TBST) and anti-CD73 (#sc-25603; dilution 1:1000 in 5% BSA in TBST) antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA); goat anti-rabbit IgG HRP (#ab205718; dilution 1:10,000 in 3% skimmed milk in TBST) and goat anti-mouse IgG HRP (#ab97023; dilution 1:10,000 in 3% skimmed milk in TBST) secondary antibodies were obtained from Abcam (Cambridge, UK).

Animals

C57BL/6J wild type (WT) and NOX2 deficient (KO) mice aged between 10 and 20 weeks were used for insulin secretion and Ca²⁺ measurements. All animals were maintained in the animal facility of the Center for Integrative Physiology and Molecular Medicine (CIPMM) of Saarland University devoid of murine pathogens. All procedures were in accordance with the ethical principles of the local ethical committee.

Pancreatic islets isolation

After full inflation with 4 ml of collagenase P in Krebs Henseleit (KH) buffer (0.63 mg/ml), pancreas was removed and incubated for 25 min in the water bath at 37°C for digestion of the exocrine portion. Pancreas was then shaken manually, washed with KH buffer and centrifuged three times (1000 rpm / 5 min). Islets were collected in a stereomicroscope and cultured for 48 h before treatments.

Cell lines

BRIN-BD11 cells were used for superoxide measurement and for the western blot of the subunit p47phox in fractions from cytosol and membrane; roGFP2-Orp1 BRIN-BD11 cells were used for the assessment of H₂O₂ production. For superoxide measurement, cells were seeded at 2.5×10⁵ per well in 500 µl medium in a 24-well plate; for translocation of p47phox, cells were seeded at 1×10⁶ per flask in 10 ml medium in 75 cm² tissue culture flasks; for H₂O₂ analysis, cells were seeded at 5×10⁴ cells per well in 200 µl medium in 96-well plates. Cells were allowed to adhere overnight and then exposed to different treatments.

Culture of BRIN-BD11 and islets

BRIN-BD11 cells, roGFP2-Orp1 BRIN-BD11 cells and mice islets were cultured at 37°C in a humidified atmosphere containing 5% CO₂ in complete RPMI 1640 medium containing 11.1 mM glucose and supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 µg/ml streptomycin.

Superoxide measurement

BRIN-BD11 cells were pre-incubated for 20 min in Krebs-Henseleit (KH) buffer supplemented with 11.1 mM glucose. After, the cells were incubated in KH buffer containing different glucose concentrations in the absence or presence of GW9508 or linoleic acid for 60 min. The fluorescence was then measured by the flow cytometer Guava EasyCyte (Merck Millipore – Billerica, MA, USA), using the DHE dye, as previously described [35].

Translocation of p47phox subunit to the membrane

To analyze the translocation of p47phox from cytosol to the plasma membrane, cells were exposed to 20 µM GW9508 in KH buffer at 5.6 mM or 16.7 mM of glucose for different periods (0, 5, 10, 20, 30 and 40 min). After incubation, cells were disrupted using extraction buffer (10 mM Tris, 1 mM EDTA and 250 mM sucrose) containing protease and phosphatase inhibitors. Content was centrifuged for 15 min at 1000 g/4°C; pellet containing the nuclear fraction was discarded. Supernatant was collected and centrifuged at 12000g/4°C for 15 min. Supernatant containing the cytosolic fraction was collected and the pellet containing the membrane fraction was resuspended in extraction buffer. Protein concentration of each fraction was quantified by Bradford reagent and 40 µg of protein were submitted to SDS-PAGE and transferred to nitrocellulose membranes to be stained with specific antibodies against the protein of interest, p47phox, and the internal control, CD73.

Small interfering RNA transfection

BRIN-BD11 cells were transfected for 7 h at 37°C in Opti-MEM medium containing Lipofectamine 2000 in the presence or absence of 40 nM of siRNA for p22phox or scramble RNA as a negative control (Santa Cruz Biotechnology, Texas, USA). After transfection, BRIN-BD11 cells were maintained in...
complete RPMI 1640 medium containing 11.1 mM glucose for additional 48 h before analysis of knockdown by western blot.

**Western blot**

Protein expression of p47phox in membrane and cytosolic fractions and of p22phox after transfection with siRNA were assessed by western blot. Total protein extracts (40 µg) were separated by SDS-PAGE and transferred to nitrocellulose membranes. Membranes were probed with specific antibodies against the proteins of interest, using anti-CD73 as internal control. Bands were quantified by densitometry using ImageJ Software.

**Hydrogen peroxide (H₂O₂) measurement**

Measurements of intracellular levels of H₂O₂ were performed in roGFP2-Orp1 BRIN-BD11 cells using the CLARIOstar Microplate Reader (BMG LABTECH, Ortenberg, Germany). Temperature was set to 37°C and atmospheric conditions were set to 5% CO₂ with the ventilation left open for O₂ to diffuse freely in the system (18.8% O₂). Protocol was divided into two steps: first in basal condition, followed by addition of different stimuli. Cytosolic roGFP emission was detected after incubation at 400 and 480 nm and emission at 500–530 nm. Fully oxidized (DA) and fully reduced (DTT) samples were prepared for the calculation of the degree of probe oxidation (OxD). The calculation of OxD values was done as previously described [36].

**Insulin secretion**

After 1 h incubation with different conditions, islets from WT and NOX2 KO mice were checked for GSIS. Groups of 10 islets were collected to fresh tubes containing KH buffer with 0.5 mM glucose and incubated at 37°C for 45 min. Supernatant was discarded and substituted by KH buffer with either 5.6 or 8.3 mM of glucose and incubated at 37°C for 60 min. Supernatant was collected and insulin release was measured by Fluorescence Resonance Energy Transfer (FRET) using the Insulin Ultra-Sensitive Assay kit (Cisbio). The signal intensity was measured at 665 and 620 nm at the CLARIOstar Microplate Reader (BMG LABTECH).

**Ca²⁺ measurements**

In order to assess total cytosolic Ca²⁺, islets from WT and NOX2 KO mice were loaded with 5 µM Fura-2 AM for 2 h in RPMI 1640 culture medium (incubated at 37°C and 5% CO₂). In the last hour of loading, GW9508 (final concentration: 20 µM) or linoleic acid (final concentration: 30 µM) were added. Islets were then washed twice for 10 min in bicarbonate buffered KH solution with 0 mM glucose. After washing, the islets were placed under the microscope Axio Observer 7 (Zeiss, Oberkochen, Germany) and measurements were made every 2 s for 30 min. Protocol was divided into two steps: first in KH buffer without glucose, followed by addition of high glucose (20 mM). Islets were imaged using excitation at 340/380 nm and emission at 505 nm.

**Statistical analysis**

Results are presented as means ± SEM. Statistical analysis was performed by One-way ANOVA followed by Dunnett, Sidak or Tukey or Two-way ANOVA followed by Tukey or Sidak, as appropriate and indicated in figure legends, using GraphPad Prism 7 software (La Jolla, CA, USA). The level of significance was considered for p<0.05.

**Results**

**Effect of 1-hour exposure to GW9508 or linoleic acid on ROS production of BRIN-BD11 cells**

We first analyzed the effect of different concentrations of the GPR40 agonist GW9508 (20, 100, 150 and 200 µM) on the primary product of NADPH oxidase activity, superoxide, after 1-hour exposure of BRIN-BD11 cells in low (5.6 mM) and high (16.7 mM) glucose concentrations (Figure 1(A)). Because GW9508 and the unsaturated FFA linoleic acid have similar binding sites to GPR40 [34], we also checked for superoxide production of BRIN-BD11 cells after 1-hour exposure to different concentrations of linoleic acid (15, 30, 50, 100 and 200 µM) in both 5.6 and 16.7 mM glucose (Figure 1(B)). Acute exposure to GW9508 promoted an increase in the total superoxide content in 5.6 mM of glucose in all concentrations tested, while in 16.7 mM glucose, the increase was seen only in 100, 150 and 200 µM (Figure 1(A)). Linoleic acid had no effect on superoxide production in any concentration tested, except for 100 µM in both 5.6 and 16.7 mM glucose (Figure 1(B)).

For next experiments, we chose 20 µM GW9508 and 100 µM linoleic acid. We then evaluated 1-hour production of superoxide in different glucose concentrations (Figure 1(C, D)). GW9508 led to increase of superoxide in 5.6 and 8.3 mM glucose and not in higher concentrations of glucose (Figure 1(C)). On the other hand, linoleic acid led to increase in superoxide in all concentrations of glucose tested (Figure 1(D)). This may be due to the fact that linoleic acid also acts through other pathways than the activation of GPR40.

As superoxide is rapidly converted into H₂O₂ by superoxide dismutases, we next checked for the production of H₂O₂ in the recently-generated BRIN-BD11 cells expressing a specific sensor for H₂O₂ in the cytosol (roGFP2-Orp1 BRIN-BD11) during 1-hour exposure to GW9508 (20 µM) or linoleic acid (30 or 100 µM) in different glucose concentrations: 5.6 mM (Figure 1(E)), 8.3 mM (Figure 1(F)) and 16.7 mM (Figure 1(G)). In 5.6 and 8.3 mM of glucose, there was an immediate increase in cytosolic H₂O₂ production right after the addition (arrow) of GW9508 and a more gradual increase after addition of 100 µM linoleic acid and only a slight increase with 30 µM linoleic acid (Figure 1(E,F)). In contrast to that, the addition of GW9508 did not lead to increase of the cytosolic H₂O₂ in 16.7 mM glucose concentration (Figure 1(G)).

**Effect of 1-hour exposure to GW9508 on the translocation of p47phox from cytosol to membrane**

The activation of the NADPH oxidase complex starts with the phosphorylation of p47phox, which promotes the migration of the cytosolic subunits to the plasma membrane and their association with membrane subunits. Therefore, to address whether NADPH oxidase was activated, the effect of the GPR40 agonist GW9508 on the translocation of the organizer subunit p47phox from cytosol to the plasma membrane was analyzed after exposure of BRIN-BD11 cells to 20 µM GW9508 in different periods (0–40 min). For this experiment, we chose 5.6 mM (Figure 2(A–D)) and 16.7 mM (Figure 2(E–H))
GW9508 and linoleic acid stimulate ROS production. (A) Production of superoxide by BRIN-BD11 cells incubated in the absence (Control) or presence of different concentrations of GPR40 agonist, GW9508, (20, 100, 150 or 200 μM) in 5.6 or 16.7 mM glucose for 60 min. Results are expressed as mean ± SEM of 3–8 independent experiments. **P<0.01 and ****P<0.0001 versus Control in corresponding glucose concentration. Two-way ANOVA followed by Dunnett. (B) Production of superoxide by BRIN-BD11 incubated in the absence (Control) or presence of different concentrations of linoleic acid (15, 30, 50, 100 or 200 μM) in 5.6 or 16.7 mM glucose for 60 min. Results are expressed as mean ± SEM of 4 independent experiments. ****P<0.0001 versus Control in corresponding glucose concentration. Two-way ANOVA followed by Sidak. (C) Production of superoxide by BRIN-BD11 cells incubated in the absence (Control) or presence of 20 μM GW9508 in different glucose concentrations (2.8, 5.6, 8.3, 11.1, 16.7 and 20 mM) for 60 min. Results are expressed as mean ± SEM of 7–8 independent experiments. *P<0.05 versus Control in corresponding glucose concentration. Two-way ANOVA followed by Sidak. (D) Production of superoxide by BRIN-BD11 cells incubated in the absence (Control) or presence of 100 μM linoleic acid (Linoleic) in different glucose concentrations: 5.6 mM (E), 8.3 mM (F) and 16.7 mM (G). Results are expressed as OxDroGFP2 of 3–6 independent experiments.

Figure 1. GW9508 and linoleic acid stimulate ROS production. (A) Production of superoxide by BRIN-BD11 cells incubated in the absence (Control) or presence of different concentrations of GPR40 agonist, GW9508, (20, 100, 150 or 200 μM) in 5.6 or 16.7 mM glucose for 60 min. Results are expressed as mean ± SEM of 3–8 independent experiments. **P<0.01 and ****P<0.0001 versus Control in corresponding glucose concentration. Two-way ANOVA followed by Dunnett. (B) Production of superoxide by BRIN-BD11 incubated in the absence (Control) or presence of different concentrations of linoleic acid (15, 30, 50, 100 or 200 μM) in 5.6 or 16.7 mM glucose for 60 min. Results are expressed as mean ± SEM of 4 independent experiments. ****P<0.0001 versus Control in corresponding glucose concentration. Two-way ANOVA followed by Sidak. (C) Production of superoxide by BRIN-BD11 cells incubated in the absence (Control) or presence of 20 μM GW9508 in different glucose concentrations (2.8, 5.6, 8.3, 11.1, 16.7 and 20 mM) for 60 min. Results are expressed as mean ± SEM of 7–8 independent experiments. *P<0.05 versus Control in corresponding glucose concentration. Two-way ANOVA followed by Sidak. (D) Production of superoxide by BRIN-BD11 cells incubated in the absence (Control) or presence of 100 μM linoleic acid (Linoleic) in different glucose concentrations (5.6, 8.3, and 16.7 mM) for 60 min. Results are expressed as mean ± SEM of 4 independent experiments. ****P<0.0001 versus Control in corresponding glucose concentration. Two-way ANOVA followed by Sidak. (A–D) Production of superoxide was analyzed by flow cytometry using DHE dye. (E–G) Dynamic production of H2O2 by BRIN-BD11 roGFP2-Orp1 cells. Arrows indicate moment of addition of different conditions. Conditions: Control, 20 μM GPR40 agonist GW9508 (GW9508), 30 μM linoleic acid and 100 μM linoleic acid in different glucose concentrations: 5.6 mM (E), 8.3 mM (F) and 16.7 mM (G). Results are expressed as OxDroGFP2 of 3–6 independent experiments.
of glucose. Analysis of cytosolic and membrane fractions was performed. In 5.6 mM glucose the organizer subunit p47phox translocated from the cytosol (Figure 2(C)) to plasma membrane (Figure 2(D)) after 10–30 min of exposure to GW9508. No translocation was observed in 16.7 mM glucose (Figure 2(E–H)). This result shows that GPR40 activation with agonist GW9508 leads to assembly of the NADPH oxidase complex in low glucose.

Effect of p22phox knockdown or pharmacological inhibition of NADPH oxidase on the superoxide content after exposure to GW9508 or linoleic acid

Next we sought to analyze the effect of NADPH oxidase on the superoxide production upon GPR40 activation. We used two approaches: (1) the pan-inhibitor of NADPH oxidase, VAS2870 and (2) siRNA of p22phox, which is the common membrane subunit for all NADPH oxidase isoforms. Treatment with VAS2870 led to decreased superoxide levels compared to control cells in 5.6 and 16.7 mM glucose (Figure 3(A)). In addition, VAS2870 was able to reduce superoxide levels when co-treated with GW9508 (Figure 3(A)). siRNA for p22phox resulted in a 48% reduction of the protein levels (Figure 3(B)). Furthermore, p22phox knockdown prevented the increase in the superoxide content due to the activation of GPR40 by GW9508, in both glucose concentrations tested (Figure 3(C)). We have also tested whether p22phox knockdown could prevent the increase in superoxide production after treatment with linoleic acid (Figure 3(D)). Indeed, siRNA for p22phox was able to decrease superoxide by 8.1% when co-treated with linoleic acid in 5.6 mM glucose, with no effect in 16.7 mM glucose (Figure 3(D)).

Effect of inhibition of NADPH oxidase on the function of β-cells after exposure to GW9508 or linoleic acid

Finally, we analyzed β-cell fitness by measuring insulin secretion and cytosolic calcium dynamics upon glucose stimulation. For functional parameters, it is well recognized that islets are better models; therefore we have used pancreatic mouse islets from Control (WT) or NOX2 KO mice.

We observed no difference in total insulin secretion upon GW9508 treatment for 1-hour in any glucose concentration (Figure 4(A,B)). However, when delta secretion was calculated (insulin secreted at 8.3 mM glucose subtracted by the insulin values in 5.6 mM glucose), GW9508 presented increased delta secretion compared to control group (Figure 4(C)). The lack of NADPH oxidase 2 had no impact on GW9508-induced insulin secretion in any glucose concentration tested (Figure 4(A–C)). Linoleic acid led to increased insulin secretion compared to control and GW9508 in both glucose concentrations (5.6 and 8.3 mM), and also presented higher delta secretion. However, NOX2 KO islets exposed to linoleic acid do not secrete different amounts of insulin compared to WT islets (Figure 4(A–C)).

Cytosolic calcium was measured during 1-hour incubation with GW9508 or 30 μM linoleic acid (Figure 4(D,E)). Upon stimulation with 20 mM glucose, no differences were observed in WT (Figure 4(D)) or NOX2 KO (Figure 4(E)) islets. However, NOX2 KO islets show less cytosolic calcium in GW9508, comparing with WT islets when delta calcium is calculated (average value on minute 14 minus average value on minute 4) (Figure 4(F)).

Discussion

The potential role of NADPH oxidase on GPR40 activation and consequently on GSIS has been explored during the last few years. Activation of the NADPH oxidase complex generates ROS that may act as second messengers for GSIS [29,30,37]. In addition, GPR40 activation by FFAs or by agonist molecules also leads to the generation of additional second messengers such as DAG, Ca2+ and cAMP, also culminating in the enhancement of insulin secretion [1,6–8,38,39].

Our group recently demonstrated that during palmitate-induced superoxide production and stimulation of GSIS, there is a crosstalk between activation of NADPH oxidase and GPR40 in pancreatic β-cells [40]. Moreover, palmitate-induced increase in GSIS was prevented by the inhibition of NADPH oxidase (with DPI or p22phox knockdown) or PKC (using calphostin) [40]. Herein, we explored whether GW9508, an agonist of GPR40, plays a role in the activation of NADPH oxidase to produce superoxide in BRIN-BD11 cells in different glucose concentrations. We also investigated whether NADPH oxidase is important for insulin secretion upon these conditions. We show that acute GPR40 activation using an agonist molecule GW9508 or linoleic acid activates NADPH oxidase and consequently increases superoxide and H2O2 levels. Interestingly, the effect was more pronounced in the presence of 5.6 and 8.3 mM of glucose, with little effect at higher glucose concentrations (16.7 mM). However, we observed no impact of deleting NADPH oxidase 2 on insulin secretion under these conditions.

The minor effects of high glucose concentration on superoxide and H2O2 are likely related to increased NADPH levels upon high glucose concentrations, as showed before [41–43]. Therefore, following glucose entry into the cell and further metabolism, NADPH is produced and used as co-factor for several ROS scavenging systems, such as glutathione reductase and thioredoxin reductase [23]. Thus, even if ROS is produced upon GPR40 activation at higher glucose concentrations, it is likely that the scavenging capacity is higher, resulting in lower net levels. In agreement, using genetically-encoded H2O2 sensors in parallel with measurements of NADPH levels, Deglasse and co-authors have shown that upon high glucose (20 mM), exogenous addition of H2O2 elicited smaller intracellular net H2O2 levels, an effect that was abolished when NADPH levels were depleted [41].

Importantly, in our study, the increase in superoxide upon GPR40 agonist was abrogated by p22phox knockdown and in cells treated with a pharmacological inhibitor of NADPH oxidase (VAS2870), demonstrating that NADPH oxidases were involved (Figure 3(A,C)). Interestingly, linoleic acid, a FFA with similar binding sites to GPR40 increased superoxide levels to a higher extent than GW9508. Inhibition of NADPH oxidase by p22phox knockdown led to significantly lower superoxide levels upon linoleic acid treatment; however not back to control levels. This is very reasonable, as linoleic acid is metabolized during beta-oxidation and can also lead to other sources of superoxide, such as peroxisomal and/or mitochondrial. Therefore, our data shows that while GW9508 leads to NADPH oxidase-dependent increase in superoxide levels, FFAs such as linoleic acid might increase superoxide through several mechanisms, including NADPH oxidase. In agreement, Elsner et al, have previously shown that upon fatty acid exposure, peroxisomes are an important source of ROS [44].
Figure 2. p47phox migration from cytosol to plasma membrane after exposure to GW9508. (A–B) Protein expression of cytosolic and membrane fractions of p47phox in BRIN-BD11 cells after GPR40 stimulation with 20 μM of GW9508 for 0, 5, 10, 20, 30 and 40 min in 5.6 mM glucose. (C) Cytosolic fractions separately. (D) Membrane fractions separately. Results are expressed as mean ± SEM of 4 independent experiments. *P<0.05. One-way ANOVA followed by Tukey. (E–F) Protein expression of cytosolic and membrane fractions of p47phox in BRIN-BD11 cells after GPR40 stimulation with 20 μM of GW9508 for 0, 5, 10, 20, 30 and 40 min in 16.7 mM glucose. (G) Cytosolic fractions separately. (H) Membrane fractions separately. Results are expressed as mean ± SEM of 4 independent experiments.
We also analyzed the effect of GW9508 on the translocation of the organizer subunit of NADPH oxidase (p47phox) from the cytosol to the plasma membrane at different time points (from 0 to 40 min) and different glucose concentrations. In agreement with superoxide and H2O2 measurements, p47phox translocates from the cytosol to the membrane between 10 and 30 min after exposure to GW9508 in 5.6 mM, but not in 16.7 mM glucose. Migration of the p47phox to the membrane, allows the assembly of the complex to produce superoxide, which is further dismutated to H2O2. Hereby we have not compared the translocation side-by-side (low vs high glucose). Therefore, it could be that upon high glucose, NADPH oxidase is already activated, as showed by others [45], and GW9508 cannot further stimulate p47phox translocation. Nevertheless, the net ROS production, i.e. result between production and removal, is shifted to lower ROS levels upon acute high glucose exposure compared to low glucose.

The stimulation of GPR40 activates a Gαq protein that increases PLC activity, which in turn induces hydrolysis of phosphatidylinositol 4,5-biphosphate (PIP2) forming IP3 and DAG. DAG activates PKC which phosphorylates p47phox, promoting its migration to the membrane and assembly of the NADPH oxidase complex [24–26]. Previously, calphostin C, an inhibitor of PKC, was shown to prevent superoxide production after exposure of insulin-secreting cells to oleate [46] and palmitate [30].

Activation of GPR40 may enhance GSIS via Gαq by two mechanisms: IP3 production and oscillation in Ca2+ and induction of PKC/PKD activation independent of Ca2+ [39]. More studies are necessary to identify by which pathway GPR40 activates NADPH oxidase. Strong evidence suggests that PKC plays a key role in this crosstalk since both activations of NADPH oxidase and GPR40 involves phosphorylation by PKC [9, 24, 47–50]. However, we cannot exclude that other...
mechanism might also be important, such as Ca\(^{2+}\) modulation of NADPH oxidases and mitochondrial \(\text{ROS-induced ROS release}\), where a positive feedback is established between mitochondria and NADPH oxidase, as demonstrated in other cell lines [51].

Contrary to what has been observed previously with INS-1E cells treated with palmitate [30], we did not observe a role of NADPH oxidase on insulin secretion upon GPR40 activation with GW9508 or linoleic acid. One of the main differences in these studies is that here we used mouse islets from wild type and mice knockout for NADPH oxidase 2, while in other studies, immortalized cell lines and protein knockdown or unspecific inhibitors of NADPH oxidase such as DPI were used. These inhibitors can act on different NADPH oxidases and also in other unspecific intracellular targets [52]. Nonetheless, we cannot exclude that other NADPH oxidases have impact on insulin secretion upon GPR40 activation. Interestingly, we found a significant difference in calcium oscillations upon GW9508 treatment in NOX2 KO mice islets, when stimulated with glucose (Figure 4(D–F)). One possible explanation is the fact that ROS can modulate calcium channels such as IP\(_3\). Indeed, studies show that exogenously added oxidants stimulate IP\(_3\)-mediated calcium release [53].

In conclusion, GW9508, an agonist of GPR40, acutely increases BRIN-BD11 superoxide and \(\text{H}_2\text{O}_2\) content in \(\beta\)-cells, an effect that was prominent in lower vs higher glucose concentrations. In these conditions, GW9508 also promotes migration of the cytosolic NADPH oxidase subunit p47\(^\text{phox}\) to plasma membrane. Furthermore, the increase in the superoxide content after exposure to GW9508 does not occur in cells with p22\(^\text{phox}\) knockdown and in cells treated with the NADPH oxidase inhibitor, VAS2870. However, NADPH oxidase 2 activation upon GW9508 does not seem to be involved in insulin secretion but plays a role in cytosolic calcium levels.

We herein report for the first time a connection between the stimulation of GPR40 and the assembly of the NADPH oxidase enzymatic complex to produce superoxide and \(\text{H}_2\text{O}_2\) in pancreatic \(\beta\)-cells, with no direct impact on insulin secretion. However, sustained superoxide and \(\text{H}_2\text{O}_2\) production could have a long-term impact on \(\beta\)-cell fitness, leading to dysfunction upon persistent GPR40 activation. Chronic GPR40 activation have been reported to be toxic in different cell types [54–59] and clinical trials using agonist molecules had to be stopped due to cellular toxicity [60]. Whether persistent production of ROS is one mechanism deserves further attention.

Acknowledgements

Thanks are due to Marlene Santos Rocha, Sandra Janku and Andrea Armbrüster for excellent technical support.

Disclosure statement

No potential conflict of interest was reported by the author(s).
Funding

This work was supported by Deutsche Forschungsgemeinschaft in the context of the SFB894 (project A13) and Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) under grant numbers 2009/53661-2 and 2009/51893-0.

ORCID

Gabriela Nunes Marsiglio-Libraris  http://orcid.org/0000-0001-8119-8335
Eloisa Aparecida Vila-Boas  http://orcid.org/0000-0003-1565-1618
Leticia Prates Roma  http://orcid.org/0000-0001-9527-0529

References

[1] Itoh Y, Kawamata Y, Harada M, et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature. 2003;426(6982):173–176.
[2] Graciano MF, Valle MM, Kowluru A, et al. Regulation of insulin secretion and reactive oxygen species production by free fatty acids in pancreatic islets. Islets. 2011;3(5):213–223.
[3] Gravena C, Mathias PC, Ashcroft SJ. Acute effects of fatty acids on insulin secretion from rat and human islets of Langerhans. J Endocrinol. 2002;173(1):73–80.
[4] Schnell S, Schaefer M, Schökel E, et al. Insulin secretion induced by palmitate–a process fully dependent on glucose concentration. Diabetes Metab. 2002;28(6 Pt 2):3537–3544. discussion 35108–12.
[5] Kotarsky K, Nilsson NE, Flodgren E, et al. A human cell surface receptor activated by free fatty acids and thiazolidinediones drug. Biochem Biophys Res Commun. 2003;301(2):406–410.
[6] Briscoe CP, Gadayon M, Andrews JL, et al. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J Biol Chem. 2003;278(13):11303–11311.
[7] Shaprio H, Shachar S, Sekler I, et al. Role of GPR40 in fatty acid action on the beta cell line INS-1/E. Biochem Biophys Res Commun. 2005;335(1):97–104.
[8] Itoh Y, Hinuma S. Free fatty acids activate the farnesoid X receptor. Biochemistry. 2005;44(13):4711–4717.
[9] Poitout V. The ins and outs of fatty acids on the pancreatic beta cell. Trends Endocrinol Metab. 2003;14(5):201–203.
[10] Schnell S, Schaefer M, Schöff C. Free fatty acids increase cytosolic free calcium and stimulate insulin secretion from beta-cells through activation of GPR40. Mol Cell Endocrinol. 2007;263(1–2):173–180.
[11] Del Guerra S, Bugliani M, D’Aleo V, et al. G-protein-coupled receptor 40 (GPR40) expression and its regulation in human pancreatic islets: the role of type 2 diabetes and fatty acids. Nutr Metab Cardiovasc Dis. 2010;20(1):22–25.
[12] Vettor R, Granotto M, De Stefani D, et al. Loss-of-function mutation of the GPR40 gene associates with abnormal stimulated insulin secretion by acting on intracellular calcium mobilization. J Clin Endocrinol Metab. 2008;93(9):3541–3550.
[13] Garrido DM, Corbett DF, Dvornik KA, et al. Synthesis and activity of small molecule GPR40 agonists. Bioorg Med Chem Lett. 2006;16(7):1840–1845.
[14] Christiansen E, Urban C, Merten N, et al. Discovery of potent and selective agonists for the free fatty acid receptor 1 (FFA1/GPR40), a potent target for the treatment of type II diabetes. J Med Chem. 2010;52(12):7061–7064.
[15] Bharate SB, Rodge A, Joshi RK, et al. Discovery of diacylphloroglucinols as a new class of GPR40 (FFAR1) agonists. Bioorg Med Chem Lett. 2008;18(24):6357–6361.
[16] Negoro N, Sasaki S, Mikami S, et al. Discovery of TAK-875: a potent, selective, and orally bioavailable GPR40 agonist. ACS Med Chem Lett. 2010;1(6):290–294.
[17] Houze JB, Zhu L, Sun Y, et al. AMG 837: a potent, orally bioavailable GPR40 agonist. Bioorg Med Chem Lett. 2012;22(2):1267–1270.
[18] Araki T, Hirayama M, Hiroi S, et al. GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes. Diabetes Obes Metab. 2012;14(3):271–278.
[19] Naik H, Vakilinejad M, Wu J, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers. J Clin Pharmacol. 2012;52(7):1007–1016.
[20] Burant CF, Viswanathan P, Marincak J, et al. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2012;379(9824):1403–1411.
[21] Leifke E, Naik H, Wu J, et al. A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes. Clin Pharmacol Ther. 2012;91(2):29–39.
[22] Kaku K, Araki T, Yoshinaka R. Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes. Diabetes Care. 2013;36(2):245–250.
[23] Roma LP, Jonas JC. Nutrient metabolism, subcellular redox state, and oxidative stress in pancreatic islets and β-cells. J Mol Biol. 2020;432(5):1461–1493.
[24] Babior BM. NADPH oxidase: an update. Blood. 1999;93(5):1464–1476.
[25] Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007;87(1):245–313.
[26] Nauseef WM. Assembly of the phagocyte NADPH oxidase. Histocommun Cell Biol. 2004;122(4):277–291.
[27] Oliveira HR, Verlengia R, Carvalho CR, et al. Pancreatic beta-cells express phagocyte-like NAD(P)H oxidase. Diabetes. 2003;52(6):1457–1463.
[28] Rebelato E, Mares-Guia TR, Graciano MF, et al. Expression of NADPH oxidase in human pancreatic islets. Life Sci. 2012;91(7–8):244–249.
[29] Morgan D, Rebelato E, Abdulkader F, et al. Association of NAD(P)H oxidase with glucose-induced insulin secretion by pancreatic beta-cells. Endocrinology. 2009;150(5):2197–2201.
[30] Graciano MF, Santos LR, Curi R, et al. NAD(P)H oxidase participates in the palmitate-induced superoxide production and insulin secretion by rat pancreatic islets. J Cell Physiol. 2011;226(4):1110–1117.
[31] Li N, Li B, Brun T, et al. NADPH oxidase NOX2 defines a new antagonistic role for reactive oxygen species and cAMP/PKA in the regulation of insulin secretion. Diabetes. 2012;61(11):2842–2850.
[32] de Souza AH, Santos LR, Roma LP, et al. NADPH oxidase-2 does not contribute to β-cell glucotoxicity in cultured pancreatic islets from C57BL/6j mice. Mol Cell Endocrinol. 2017;439:354–362.
[33] Briscoe CP, Peat AJ, McKeown SC, et al. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. Br J Pharmacol. 2006;148(5):619–628.
[34] Sum CS, Tikhonova IG, Neumann S, et al. Identification of residues important for agonist recognition and activation in GPR40. J Biol Chem. 2007;282(40):29248–29255.
[35] Graciano MF, Leonelli M, Curi R, et al. Omega-3 fatty acids control productions of superoxide and nitrogen oxide and insulin content in INS-1E cells. J Physiol Biochem. 2016;72(4):699–710.
[36] Meyer AJ, Dick TP. Fluorescent protein-based redox probes. Antioxid Redox Signal. 2010;13(5):621–650.
[37] Morgan D, Oliveira-Emilio HR, Keane D, et al. Glucose, palmitate and pro-inflammatory cytokines modulate production and activity of a phagocyte-like NADPH oxidase in rat pancreatic islets and a clonal beta cell line. Diabetologia. 2007;50(2):359–369.
[38] Tsuda N, Kawaji A, Sato T, et al. A novel free fatty acid receptor 1 (GPR40/FFAR1) agonist, MR1704, enhances glucose-dependent β-cell glucotoxicity in cultured pancreatic islets from C57BL/6J mice. Mol Cell Endocrinol. 2017;439:354–362.
[39] Briscoe CP, Peat AJ, McKeown SC, et al. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. Br J Pharmacol. 2006;148(5):619–628.
Rebelato E, Abdulkader F, Curi R, et al. Control of the intracellular redox state by glucose participates in the insulin secretion mechanism. PLoS One. 2011;6(8):e24507.

Elsner M, Gehrmann W, Lenzen S. Peroxisome-generated hydrogen peroxide as important mediator of lipotoxicity in insulin-producing cells. Diabetes. 2011;60(1):200–208.

Morgan D, Oliveira-Emilio HR, Keane D, et al. Glucose, palmitate and pro-inflammatory cytokines modulate production and activity of a phagocyte-like NADPH oxidase in rat pancreatic islets and a clonal beta cell line. Diabetologia. 2007;50(2):359–369.

Santos LR, Rebelato E, Graciano MF, et al. Oleic acid modulates metabolic substrate channeling during glucose-stimulated insulin secretion via NAD(P)H oxidase. Endocrinology. 2011;152(10):3614–3621.

Babior BM. The leukocyte NADPH oxidase. Isr Med Assoc J. 2002;4(11):1023–1024.

Fontayne A, Dang PM, Gougerot-Pocidalo MA, et al. Phosphorylation of p47phox sites by PKC alpha, beta II, delta, and zeta: effect on binding to p22phox and on NADPH oxidase activation. Biochemistry. 2002;41(24):7743–7750.

Inoguchi T, Li P, Umeda F, et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes. 2000;49(11):1939–1945.

Kristinsson H, Bergsten P, Sargsyan E. Free fatty acid receptor 1 (FFAR1/GPR40) signaling affects insulin secretion by enhancing mitochondrial respiration during palmitate exposure. Biochim Biophys Acta. 2015;1853(12):3248–3257.

Zinkevich NS, Guterman DD. ROS-induced ROS release in vascular biology: redox-redox signaling. Am J Physiol Heart Circ Physiol. 2011;301(3):H647–H653.

Reis J, Massari M, Marchese S, et al. A closer look into NADPH oxidase inhibitors: Validation and insight into their mechanism of action. Redox Biol. 2020;32:101466.

Bánsághi S, Golenár T, Madesh M, et al. Isoform- and species-specific control of inositol 1,4,5-trisphosphate (IP3) receptors by reactive oxygen species. J Biol Chem. 2014;289(12):8170–8181.

Steneberg P, Rubins N, Bartoo-Shifman R, et al. The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metab. 2005;1(4):245–258.

Zhang X, Yan G, Li Y, et al. DC260126, a small-molecule antagonist of GPR40, improves insulin tolerance but not glucose tolerance in obese Zucker rats. Biomed Pharmacother. 2010;64(9):647–651.

Wu J, Sun P, Zhang X, et al. Inhibition of GPR40 protects MIN6 β cells from palmitate-induced ER stress and apoptosis. J Cell Biochem. 2012;113(4):1152–1158.

Abaraviciene S M, Lundquist I, Galvanovskis J, et al. Palmitate-induced beta-cell dysfunction is associated with excessive NO production and is reversed by thiazolidinedione-mediated inhibition of GPR40 transduction mechanisms. PLoS One. 2008;3(5):e2182.

Kristinsson H, Smith DM, Bergsten P, et al. FFAR1 is involved in both the acute and chronic effects of palmitate on insulin secretion. Endocrinology. 2013;154(11):4078–4088.

Natalicchio A, Labarbuta R, Tortosa F, et al. Exendin-4 protects pancreatic beta cells from palmitate-induced apoptosis by interfering with GPR40 and the MKK4/7 stress kinase signalling pathway. Diabetologia. 2013;56(11):2456–2466.

Menon V, Lincoff AM, Nicholls SJ, et al. Fasiglifam-Induced Liver Injury in Patients With type 2 diabetes: Results of a Randomized Controlled Cardiovascular Outcomes Safety Trial. Diabetes Care. 2018;41(12):2603–2609.